Details for Patent: 6,828,299

Title:	Polyhydroxy glycopeptide derivatives
Abstract:	Disclosed are polyhydroxy derivatives of glycopeptides and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
Inventor(s):	Yang; Guang (San Mateo, CA), Schmidt, Jr.; Donald E. (Brisbane, CA), Judice; J. Kevin (El Granada, CA)
Assignee:	Theravance, Inc. (South San Francisco, CA)
Filing Date:	May 01, 2001
Application Number:	09/847,061
Claims:	1. A modified glycopeptide of formula II: ##STR18## wherein: R.sup.3 is --OH; R.sup.5 is hydrogen; R.sup.19 is hydrogen; R.sup.20 is --CH.sub.2 --CH(OH)CH(OH)CH.sub.2 --Y--R.sup.b (Z).sub.x or --CH.sub.2 --CH(OH)CH(OH)CH.sub.2 --R.sup.17 ; within R.sup.20 moiety R.sup.17 is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl or heterocyclic; within moiety R.sup.20 Y is selected from the group consisting of oxygen, sulfur, --S--S--, NR.sup.c --, --S(O)--, --SO.sub.2 --, --NR.sup.c C(O)--, --OSO.sub.2 --, --OC(O)--, --NR.sup.c SO.sub.2 --, --C(O)NR.sup.c --, --C(O)O--, --SO.sub.2 NR.sup.c --, --SO.sub.2 O--, --P(O)(OR.sup.c)O--, --P(O)(OR.sup.c)NR.sup.c --, --OP(O)(OR.sup.c)O--, --OP(O)(OR.sup.c)NR.sup.c --, --OC(O)O--, --NR.sup.c C(O)O--,--NR.sup.c C(O)NR.sup.c --, --OC(O)NR.sup.c --, --C(.dbd.O)--and --NR.sup.c SO.sub.2 NR.sup.c --; within R.sup.20 moiety each Z is independently selected from the group consisting of hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic and x is 1 or 2; within Y moiety R.sup.b is selected from the group consisting of a covalent bond, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene, provided R.sup.b is not a covalent bond when Z is hydrogen; each R.sup.c is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and --C(O)R.sup.d ; within R.sup.c moiety each R.sup.d is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic; and or a pharmaceutically acceptable salt or a stereoisomer thereof. 2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1. 3. The pharmaceutical composition of claim 2, wherein the composition further comprises a cyclodextrin. 4. The glycopeptide of claim 1, wherein R.sup.20 is --CH.sub.2 --CH(OH)CH(OH)CH.sub.2 --R.sup.17 and R.sup.17 is alkyl. 5. The glycopeptide of claim 1, wherein R.sup.20 is --CH.sub.2 --CH(OH)CH(OH)CH.sub.2 --R.sup.17 and R.sup.17 is aryl. 6. The glycopeptide of claim 1, wherein R.sup.20 is --CH.sub.2 --CH(OH)CH(OH)CH.sub.2 --Y--R.sup.b --(Z).sub.x and Y is an --NH--group Z is independently selected from the group consisting of hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic; and x is 1 or 2. 7. The glycopeptide of claim 1, wherein R.sup.20 is --CH.sub.2 --CH(OH)CH(OH)CH.sub.2 --Y--R.sup.b --(Z).sub.x and Y is oxygen Z is independently selected from the group consisting of hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic; and x is 1 or 2. 8. The glycopeptide of claim 1, wherein R.sup.20 is --CH.sub.2 --CH(OH)CH(OH)CH.sub.2 --Y--R.sup.b --(Z).sub.x and Y is sulfur Z is independently selected from the group consisting of hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic; and x is 1 or 2. 9. The glycopeptide of claim 1, wherein R.sup.20 is --CH.sub.2 --CH(OH)CH(OH)CH.sub.2 --Y--R.sup.b --(Z).sub.x and R.sup.b is alkylene Z is independently selected from the group consisting of hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic; and x is 1 or 2. 10. The glycopeptide of claim 1, wherein R.sup.20 is --CH.sub.2 --CH(OH)CH(OH)CH.sub.2 --Y--R.sup.b --(Z).sub.x and Z is hydrogen and x is 1 or 2. 11. The glycopeptide of claim 1, wherein R.sup.20 has the structure: ##STR19## 12. The glycopeptide of claim 1, wherein R.sup.20 has the structure: ##STR20## 13. The glycopeptide of claim 1, wherein R.sup.20 has the structure: ##STR21## 14. The glycopeptide of claim 1, wherein R.sup.20 has the structure: ##STR22## 15. A method of treating a bacterial disease in a mammal comprising administering to the mammal a therapeutically effective amount of a glycopeptide of claim 1. 16. A method of treating a bacterial disease in a mammal comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition of claim 2.